CooperVision Names Steven Robins as President, Americas
Monday, January 27 2025 | 11 h 56 min | News
CooperVision has appointed Steven Robins as President, Americas, effective immediately. He is a three-decade healthcare veteran, with several previous high-profile corporate leadership and consulting roles in the vision care industry.
Robins was most recently Managing Partner and Principal for New England Consulting Group, where he worked with a range of Fortune 500 organizations across the medical device, pharmaceutical, and OTC/vitamin sectors. Among these were strategic engagements with CooperVision, including the U.S. introduction of its MiSight® 1 day contact lens† for myopia control.
He has also served as Chief Marketing Officer and President of North American Vision Care for Bausch + Lomb, General Manager of Johnson & Johnson’s Consumer Healthcare business in Canada, and Group Marketing Director for Pfizer Consumer Healthcare.
“Steven has been working with CooperVision for a number of years on strategic, priority projects including our MiSight® 1 day contact lenses. I am impressed with his strategic thinking as well as his passion for the industry and our customers. He is a charismatic, engaging leader who undoubtedly will drive positive impacts throughout our Americas business.”
Debbie Olive, Chief Commercial Officer, CooperVision
“Since my first foray into ocular health almost 20 years ago, I have known that there’s something special about this industry, shown by the way its professionals and products come together to make the world better for millions of people every day. There are big opportunities in vision care, and CooperVision is a clear leader in several. It’s a privilege to join the company that has its sights set on becoming an even greater part of people’s lives through remarkable innovations and partnerships,” said Robins.
Robins holds a Bachelor of Arts from Bates College and has participated in the Pfizer Global Leadership Program with Harvard University. He plans to relocate to Rochester, N.Y., a community that he called home for several years.
Click HERE for the press release.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!
References:
† Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the potential impact of new management and CooperVision’s opportunities in the Americas region. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.
Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to research and development, regulatory requirements, clinical studies, sales, marketing, and distribution plans and capabilities; potential product performance and quality issues; intellectual property risks; competition; and other factors described in CooperCompanies’ Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in Cooper’s Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company’s analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
